Ticagrelor for the treatment of arterial thrombosis

Bibliography

• Braunwald E, Angiolillo D, Bates E, Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. Clin Cardiol 2008;31(3 Suppl 1):I2-9
   PubMedGoogle Scholar
• Murugappa S, Kunapuli SP. The role of ADP receptors in platelet function. Front Biosci 2006;11:1977-86
   PubMed Web of Science ®Google Scholar
• Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost 2008;99:466-72
   PubMed Web of Science ®Google Scholar
• Gawaz M, Favaloro EJ. Platelets, inflammation and cardiovascular diseases. New concepts and therapeutic implications. Semin Thromb Hemost 2010;36:129-30
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Guyer K, Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. Thromb Res 2007;119:563-70
   PubMed Web of Science ®Google Scholar
• Bonello L, Tantry US, Marcucci R, Consensus and future directions on the definition of high on-treatment platelet reactivity to ADP. J Am Coll Cardiol 2010; In press
   Google Scholar
• Gurbel PA, Tantry US. The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome. J Interv Cardiol 2008;21(Suppl 1):S10-17
   PubMedGoogle Scholar
• Reinhart KM, White CM, Baker WL. Prasugrel: a critical comparison with clopidogrel. Pharmacotherapy 2009;29:1441-51
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, ; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15
   PubMed Web of Science ®Google Scholar
• Husted S, van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther 2009;27:259-74
   PubMed Web of Science ®Google Scholar
• van Giezen JJ, Berntsson P, Zachrisson H, Bjorkman JA. Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis. Thromb Res 2009;124:565-71
   PubMed Web of Science ®Google Scholar
• Van Giezen JJ, Berntsson P, Nilsson L, Wissing BM. Direct oral P2Y12 receptor antagonist AZD6140 potently and reversibly binds to the rh-P2Y12 receptor expressed on CHO-K1 cells [abstract P207]. Arterioscler Thromb Vasc Biol 2008;28:e-72
   Google Scholar
• Van Giezen JJ, Nilsson L, Berntsson P, Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost 2009;7:1556-65
   PubMed Web of Science ®Google Scholar
• Peters G, Robbie G. Single dose pharmacokinetics and pharmacodynamics of AZD6140. Haematologica 2004;89(Suppl 7):14-15
   Google Scholar
• Butler K, Teng R. AZD6140, the first reversible oral platelet P2Y12 receptor antagonist, exhibits linear pharmacokinetics following multiple doses in healthy subjects, with greater and less variable inhibition of platelet aggregation compared with clopidogrel [abstract 562]. Can J Clin Pharmacol 2008;15:e684-5
   Google Scholar
• Peters GR, Butler KA, Winter HR. Multiple-dose pharmacokinetics (PK) and pharmacodynamics (PD) of the oral reversible, orally active ADP receptor antagonist AZD6140. Eur Heart J 2006;27(Suppl 1):P4556
   Google Scholar
• Husted S, Emanuelsson H, Heptinstall S, Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038-47
   PubMed Web of Science ®Google Scholar
• Cannon CP, Husted S, Harrington RA, ; for the DISPERSE-2 Investigators. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of theDISPERSE-2 trial. J Am Coll Cardiol 2007;50:1844-51
   PubMedGoogle Scholar
• Storey RF, Husted S, Harrington RA, Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007;50:1852-6
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57
   PubMed Web of Science ®Google Scholar
• Schomig A. Ticagrelor – is there need for a new player in the antiplatelet-therapy field? N Engl J Med 2009;361:1108-11
   PubMed Web of Science ®Google Scholar
• Cannon CP, Harrington RA, James S, ; PLATelet inhibition and patient Outcomes Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasivestrategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010;375:283-93
   PubMed Web of Science ®Google Scholar
• Held C, Bassand J-P, Becker RC, Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery; results from the PLATO trial. Presented at American College of Cardiology Meetings; March 14 – 16, 2010; Atlanta
   Google Scholar
• Steg G, Stefen J, Harrington RA, PLATO STEMI: outcomes in patients with STEMI and planned PCI. Presented at American Heart Association Meetings; November 14 – 17, 2009; Orlando
   Google Scholar
• Gurbel PA, Bliden KP, Butler K, Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009;120:2577-85
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010;121:1188-99
   PubMed Web of Science ®Google Scholar
• Storey RF, Bliden KP, Patil SB, Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel or placebo in the ONSET/OFFSET study. J Am Coll Cardiol 2010;56:185-93
   PubMed Web of Science ®Google Scholar
• Husted SE, Gurbel PA, Bliden KP, Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery diseases. Presented at American Heart Association Meetings; November 14 – 17, 2009; Orlando
   Google Scholar
• Hamm CW. Bleeding management and pharmacological strategy in primary percutaneous coronary intervention. Eur Heart J 2009;11:C9-12
   Google Scholar
• Bjorkman JA, Kirk I, van Giezen JJJ. AZD6140 inhibits adenosine uptake into erythrocytes and enhances coronary blood flow after local ischemia or intracoronary adenosine infusion [abstract 245]. Circulation 2007;116(Suppl):II-28
   Google Scholar
• Forman MB, Stone GW, Jackson EK. Role of adenosine as adjunctive therapy in acute myocardial infarction. Cardiovasc Drug Rev 2006;24:116-47
   PubMed Web of Science ®Google Scholar